Nanion Corporate Blog


05.10.2020 - Poster - Reliable Identification of hERG Liability in Drug Discovery

Reliable Identification of hERG Liability in Drug Discovery by Automated Patch Clamp


The Comprehensive in Vitro Proarrhythmia Assay (CiPA) was initiated in 2013 to improve pre-clinical drug safety paradigms. The aims of the initiative are not only to ensure that drugs which reach the market are safe, but also to reduce the number of false positives; thus ensuring that more potentially useful (and safe) drugs reach the market. As part of this initiative, compounds representing high, intermediate, and low proarrhythmic risk categories were tested across multiple sites and automated patch clamp (APC) platforms. Resulting IC50 values varied between platforms, which could be due to non-specific binding of compounds in well-based platforms (since they don’t maintain a constant flow of compound-containing solution to replenish losses to fluidics and well walls).

Download the Poster Here

Back to Overview


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.